Background Whether and to what extent complement is activated in acute myocardial infarction (AMI) and how it contributes to inflammation of the ischemic area are not yet clear. Fibrinolytic agents used for thrombolysis are known to activate complement in vitro and may contribute to its activation in vivo. The aim of this study was to measure the extent of complement activation in AMI patients, some treated and some not treated with streptokinase. In addition, because abrupt complement activation in vivo is usually associated with leukocyte margination, plugging of cells in the microcirculation, and hypotension, we correlated complement activation with leukocyte numbers and mean arterial pressure.
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Methods and Results Forty AMI patients were studied: 20 were treated with streptokinase (1.5 million IU IV over 60 minutes), and 20 were not given any fibrinolytic agent. The extent and severity of AMI were not significantly different in both groups. Blood samples were drawn on arrival at the hospital, during streptokinase infusion, and then daily for 1 week. Timematched samples were also drawn from patients not treated with streptokinase. We measured plasma levels of anaphylatoxin C4a anginal patients (C4a, 396±75; C3a, 248±+73; CSa <10; and SC5b-9, 355 +68 ng/mL) and normal healthy volunteers, although levels slightly higher than the normal range were occasionally observed.
There were striking increases in C4a, C3a, and SC5b-9 during streptokinase infusion (Fig 1) . The highest levels of C3a (3219±844 ng/mL) and C4a (3699±656 ng/mL) were measured 15 minutes after starting streptokinase, whereas the highest SC5b-9 levels (2204±626 ng/mL) were measured at the 60th minute of infusion. These complement parameters were still significantly high 1 hour after the end of the streptokinase infusion (Fig 1) . There were no increases in plasma levels of C4a, C3a, and SC5b-9 24 hours later and up to 7 days later (data not shown). No C4, 35+2; C3, 77±6; the day after: C4, 33±2; C3, 72±5).
Patients not treated with streptokinase had no significant increases in anaphylatoxin or SC5b-9 plasma levels, either in plasma collected at times matching those during streptokinase infusion (Fig 1) or in the following week. Angina patients also did not show any signs of complement activation (observation limited to the first 24 hours after arrival at the hospital).
A transient leukopenia (-29.5+7.0%; paired t test, P=.001) was observed 15 minutes after the beginning of streptokinase infusion because of a reduction of circulating polymorphonuclear cells (PMNs), followed by an increase in the number of circulating cells (Fig 2) 
Discussion
The main information provided by our study is that streptokinase given for AMI therapy abruptly activates the complement system and produces a transient leukopenia. We observed, in fact, striking increases during streptokinase treatment in three different complement activation byproducts: C4a, C3a, and SC5b-9 complexes. Complement activation appeared to be drug related because complement catabolic peptide levels in a group of AMI patients, comparable for extent of the infarcted area, severity, and clinical outcome but not treated with streptokinase, were not significantly increased. The group of angina patients also had no signs of complement activation.
Previous observations have clearly demonstrated an in situ deposition of complement components in the myocardia of patients who died because of AMI or animals with ligated coronary arteries.1,2 The lack of an increase of complement anaphylatoxins or SC5b-9 in non-streptokinase-treated AMI patients does not rule out that complement activation may have occurred in the ischemic area. Such activation might not cause detectable levels of complement catabolic peptides in the peripheral circulation. Previous observations may indicate that ischemia by itself is able to cause enough complement activation to be detected in the circulation.3'4 However, one of these publications indicates an activation that did not involve the different complement components proportionally.4 Differences in the severity of the clinical condition might explain the discrepancies between our data and those of the other study3 (we also found baseline levels of anaphylatoxins and SC5b-9 higher than the normal range in two non-streptokinasetreated patients who died from cardiogenic shock). On the other hand, our data appear to agree with those of a previous report of normal plasma anaphylatoxin levels in AMI.6 Moreover, Bennett et a15 reported normal plasma anaphylatoxin levels in the early phases of AMI before thrombolysis and a significant increase after rt-PA administration, before any angiographically detectable reperfusion. Although our study did not include an angiographic demonstration that complement activation by streptokinase preceded reperfusion, the hypothesis that complement activation is due to reperfusion injury appears to be unlikely when one examines the difference in the time courses of the complement activation and coronary reperfusion.16,17 Signs of complement activation were found in a few samples collected as early as 5 minutes after streptokinase infusion was started (data not shown).
The group of patients treated with streptokinase had higher, although not significantly, peak levels of CPK. However, the fact that the levels of C4a, C3a, and SC5b-9 on arrival at the hospital were not significantly elevated in both streptokinase-untreated and treated patients makes it hardly conceivable that the high levels of complement components measured during streptokinase infusion were due to larger infarcts in this group.
The complement activation caused by streptokinase infusion involves the classic pathway, since C4a levels are clearly increased. The activation involves C3 as well as the terminal components C5 to C9. The increases in C3a and C4a started immediately after the beginning of infusion and peaked 15 minutes later, whereas, as expected, the SC5b-9 peak was slightly later. Streptoki We found a decrease in MAP during streptokinase treatment. This phenomenon has been reported previously, and it is independent of the size and site of the infarcted area.22 This decrease coincides in time with the release of anaphylatoxin. This suggests that hypotension may be at least partially complement mediated, even if a quantitative correlation between the extent of complement activation and blood pressure fall is lacking. Other mechanisms may contribute to the streptokinase-mediated hypotension. Plasmin, for example, facilitates bradykinin generation by acting on high-molecular-weight kininogen. 23 We are currently studying the role of bradykinin in the pathogenesis of streptokinase-mediated hypotension.
Conclusions
Our study demonstrates that (1) uncomplicated AMI does not cause activation of the complement system detectable in the blood stream; (2) streptokinase treatment causes abrupt complement activation through the classic pathway; and (3) complement activation entails transient leukopenia and possibly contributes to hypotension during streptokinase infusion.
